CRVS Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies...

Stats
Today's Volume	64 873.00
Average Volume	198 893
Market Cap	72.58M
EPS	$0 ( 2024-03-26 )
Next earnings date	( $-0.120 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.64
ATR14	$0.0220 (1.52%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-28	Arcara Jeffrey	Buy	400 000	Stock Option (Right to Buy)
2024-02-02	Arcara Jeffrey	Buy	0
2023-12-06	Miller Richard A Md	Buy	500 000	Stock Option (Right to Buy)
2023-12-06	Lea Leiv	Buy	200 000	Stock Option (Right to Buy)
2023-12-06	Jones William Benton	Buy	200 000	Stock Option (Right to Buy)

INSIDER POWER
100.00
Last 97 transactions
Buy: 8 310 910 \| Sell: 8 757 350

Volume Correlation

Long: 0.02 (neutral)

Short: -0.49 (neutral)

Signal:(45.257) Neutral

Corvus Pharmaceuticals Correlation

10 Most Positive Correlations
GNLN	0.95
VTGN	0.947
AQST	0.943
LIXT	0.936
OMCL	0.924
FLGC	0.921
BBLG	0.92
NNOX	0.917
NERV	0.914
APTO	0.914

10 Most Negative Correlations
PRAA	-0.957
PEBK	-0.95
IEP	-0.931
LEXX	-0.928
FOXF	-0.927
CRWS	-0.916
PROV	-0.911
FARO	-0.911
VORB	-0.91
PINC	-0.909

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Corvus Pharmaceuticals Correlation - Currency/Commodity

-0.10
( neutral )

0.21
( neutral )

0.00
( neutral )

-0.24
( neutral )

0.55
( weak )

0.09
( neutral )

Corvus Pharmaceuticals Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-151 000 (0.00 %)
EPS:	$-0.560

Q4	2023
Revenue:	$0
Gross Profit:	$-28 000.00 (0.00 %)
EPS:	$-0.140

Q3	2023
Revenue:	$0
Gross Profit:	$-30 000.00 (0.00 %)
EPS:	$-0.120

Q2	2023
Revenue:	$0
Gross Profit:	$-36 000.00 (0.00 %)
EPS:	$-0.140

Financial Reports:

No articles found.

Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies. Its lead product candidate is Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, which is in Phase Ib/II clinical trial for non-small cell lung cancer and head and neck cancers. The company also develops CPI-818, a covalent inhibitor of ITK, which is in Phase I/Ib clinical trial to treat patients with various malignant T-cell lymphomas, as well as designed to inhibit the proliferation of certain malignant T-cells; and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor that is in Phase II clinical trial for patients with either advanced or refractory renal cell cancer. Its preclinical stage products include CPI-182, an antibody designed to block inflammation and myeloid suppression; and CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a strategic collaboration with Angel Pharmaceuticals for the development its pipeline of targeted investigational medicines. The company was incorporated in 2014 and is based in Burlingame, California.